Life Science Compliance Update

December

2017

Mylan’s “Banquet of Consequences” Ends for Now with the Latest EpiPen Settlement

Written by , Posted in Uncategorized

Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update

Mylan has been the subject of bad press for roughly a year now. Fortunately, it seems as though the firestorm surrounding the company – including the EpiPen price saga – may be over for now. This article outlines a recent suit filed by a Mylan competitor and the settlement and CIA that resulted. It concludes with insight from a prominent CEO about how compliance officers and other executives can avoid the negative press Mylan has endured.


   or   

Topic tags:

November

2017

The Expanding Frontier Part 3 – PAGs in Light of the Aegerion Cases

Written by , Posted in Uncategorized

Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update

There is no doubt that Patient Advocacy Groups play an important and substantial role in shaping the healthcare landscape. It also is true that it is not a simple matter for life sciences companies to work with these groups. This article examines the recent trio of cases involving Aegerion to ascertain what it says about the government’s enforcement stance and how that it may shape the future of industry/PAG interactions.


   or   

Topic tags:

Gravityscan Badge
Menu Title